Home The Word Brain My Amedeo FAQ Privacy About   

As of October 2023, Amedeo had
12,263 active subscribers

  HIV Infection

  Free Subscription

Articles published in Antivir Ther

Retrieve available abstracts of 40 articles:
HTML format

Single Articles

    December 2023
  1. BERKO J, Mazonson P, Short D, Karris M, et al
    Waitlist-controlled trial of an online intervention to address mental health among older people living with HIV.
    Antivir Ther. 2023;28:13596535231216311.
    PubMed     Abstract available

    October 2023
  2. CARR A, Mackie NE, Paredes R, Ruxrungtham K, et al
    HIV drug resistance in the era of contemporary antiretroviral therapy: A clinical perspective.
    Antivir Ther. 2023;28:13596535231201162.
    PubMed     Abstract available

    June 2023
  3. ABERG JA, Mills A, Moreno S, Slater J, et al
    The evolution of clinical study design in heavily treatment-experienced persons with HIV: A critical review.
    Antivir Ther. 2023;28:13596535231174774.
    PubMed     Abstract available

  4. ARMSTRONG I, Lacombe-Duncan A, Shokoohi M, Persad Y, et al
    Feminizing hormone therapy in a Canadian cohort of transgender women with and without HIV.
    Antivir Ther. 2023;28:13596535231182505.
    PubMed     Abstract available

  5. ZILWA N, Mpejane O, Mehboob G, Gill S, et al
    Fanconi syndrome, diabetes insipidus, and acute kidney injury due to tenofovir disoproxil fumarate: A case report.
    Antivir Ther. 2023;28:13596535231186727.
    PubMed     Abstract available

    April 2023
  6. SUWANLERK T, Rupasinghe D, Jantarabenjakul W, An VT, et al
    Lipid and glucose abnormalities and associated factors among children living with HIV in Asia.
    Antivir Ther. 2023;28:13596535231170751.
    PubMed     Abstract available

    February 2023
  7. PETERS E, Iwuji AC
    Efficacy, safety and tolerability of Biktarvy in HIV-1 infection: A scoping review.
    Antivir Ther. 2023;28:13596535231159030.
    PubMed     Abstract available

  8. ROLLE CP, Castano J, Nguyen V, Patel K, et al
    Treatment-related early discontinuations and adverse events among newly diagnosed people living with HIV initiating integrase inhibitors in a real-world setting.
    Antivir Ther. 2023;28:13596535231163703.
    PubMed     Abstract available

  9. DE WAAL R, Rabie H, Technau KG, Eley B, et al
    Abacavir safety and effectiveness in young infants with HIV in South African observational cohorts.
    Antivir Ther. 2023;28:13596535231168480.
    PubMed     Abstract available

    October 2022
  10. ARA T, Endo T, Goto H, Kasahara K, et al
    Antiretroviral therapy achieved metabolic complete remission of hepatic AIDS related Epstein-Barr virus-associated smooth muscle tumor.
    Antivir Ther. 2022;27:13596535221126828.
    PubMed     Abstract available

  11. KRYSTAL M, Chabria S, Austin D, Wolstenholme A, et al
    A Phase 1 randomized study of GSK3732394, an investigational long-acting biologic treatment regimen for HIV-1 infection.
    Antivir Ther. 2022;27:13596535221131164.
    PubMed     Abstract available

  12. TYAGI A, Tong Y, Rabideau DJ, Reynolds Z, et al
    Antiretroviral therapy adherence patterns, virological suppression, and emergence of drug resistance: A nested case-control study from Uganda and South Africa.
    Antivir Ther. 2022;27:13596535221114822.
    PubMed     Abstract available

    August 2022
  13. ALEJOS B, Diez C, Galindo MJ, Lopez JC, et al
    Progress in the quality of care for newly diagnosed people with HIV in Spain (2004-2019).
    Antivir Ther. 2022;27:13596535221112729.
    PubMed     Abstract available

  14. BELLO G, Kagoli M, Chipeta S, Auld A, et al
    Resistance levels to non-nucleoside reverse transcriptase inhibitors among pregnant women with recent HIV infection in Malawi.
    Antivir Ther. 2022;27:13596535221121225.
    PubMed     Abstract available

  15. ALVAREZ E, Campbell L, Tinago W, Garcia-Leon A, et al
    The renal-bone axis in older people living with HIV on stable antiretroviral therapy: A sub-analysis of the GS-US-104-0423 study.
    Antivir Ther. 2022;27:13596535221094898.
    PubMed     Abstract available

  16. VAN DER VEER MA, Jacobs TG, Bukkems LH, Colbers AP, et al
    Pharmacokinetic interaction between raltegravir and rifampicin in an infant with HIV exposed to active TB: a case report.
    Antivir Ther. 2022;27:13596535221119932.
    PubMed     Abstract available

    June 2022
  17. MUSENGIMANA G, Tuyishime E, Kiromera A, Malamba SS, et al
    Acquired HIV drug resistance among adults living with HIV receiving first-line antiretroviral therapy in Rwanda: A cross-sectional nationally representative survey.
    Antivir Ther. 2022;27:13596535221102690.
    PubMed     Abstract available

  18. WISCH JK, Cooley SA, Yarasheski KE, Cade WT, et al
    Socioeconomic status largely explains integrase inhibitors-related body composition differences in chronically infected men living with HIV.
    Antivir Ther. 2022;27:13596535221109748.
    PubMed     Abstract available

  19. EUROPEAN PREGNANCY AND PAEDIAT, Lyons A, Thompson L, Chappell E, et al
    Outcomes of etravirine-based antiretroviral treatment in treatment-experienced children and adolescents living with HIV in Europe and Thailand.
    Antivir Ther. 2022;27:13596535221092182.
    PubMed     Abstract available

    April 2022
  20. LEE WA, Cheng AK
    Tenofovir alafenamide fumarate.
    Antivir Ther. 2022;27:13596535211067600.
    PubMed     Abstract available

  21. ABDOOL KARIM SS, Baxter C, Abdool Karim Q
    Advancing HIV prevention using tenofovir-based pre-exposure prophylaxis.
    Antivir Ther. 2022;27:13596535211067589.
    PubMed     Abstract available

  22. CHOUDHARY MC, Mellors JW
    The transformation of HIV therapy: One pill once a day.
    Antivir Ther. 2022;27:13596535211062396.
    PubMed     Abstract available

  23. ALTON G, Samuel C, Reddi A
    Providing access to high-quality, low-cost medicines across low and middle-income countries (LMICs), working with governments and generic manufacturers around the globe - A business case.
    Antivir Ther. 2022;27:13596535211068617.
    PubMed     Abstract available

  24. SCHINAZI RF, Patel D, Ehteshami M
    The best backbone for HIV prevention, treatment, and elimination: Emtricitabine+tenofovir.
    Antivir Ther. 2022;27:13596535211067599.
    PubMed     Abstract available

  25. YANG T, Oliyai R, Kent KM
    The making of the one pill-Developing single tablet regimens for HIV and for HCV.
    Antivir Ther. 2022;27:13596535211067606.
    PubMed     Abstract available

    November 2021
  26. MOLINA JM, Ene L, Cahn P, Fatkenheuer G, et al
    Long-term safety and efficacy of rilpivirine in combination with nucleoside/nucleotide reverse transcriptase inhibitors in HIV-1 infected patients: 336-week rollover study of phase 2b and 3 clinical studies.
    Antivir Ther. 2021;26.
    PubMed     Abstract available

  27. RIVERA AS, Machenry S, Okpokwu J, Olatunde B, et al
    HBV co-infection is associated with persistently elevated liver stiffness measurement in HIV-positive adults: A 6-year single-centre cohort study in Nigeria.
    Antivir Ther. 2021;26.
    PubMed     Abstract available

  28. PRESSIAT C, Dainguy E, Treluyer JM, Yonaba C, et al
    Comparison of three galenic forms of lamivudine in young West African children living with Human Immunodeficiency Virus.
    Antivir Ther. 2021;26.
    PubMed     Abstract available

    May 2021
  29. MAGGIOLO F, Gianotti N, Comi L, Di Filippo E, et al
    Rilpivirine plus cobicistat-boosted darunavir as alternative to standard three-drug therapy in HIV-infected, virologically suppressed subjects: Final results of the PROBE 2 trial.
    Antivir Ther. 2021;26.
    PubMed     Abstract available

  30. SCHEIBE K, Urbanska A, Jakubowski P, Hlebowicz M, et al
    Low prevalence of doravirine-associated resistance mutations among polish human immunodeficiency-1 (HIV-1)-infected patients.
    Antivir Ther. 2021;26.
    PubMed     Abstract available

  31. FARINACCI D, Ciccullo A, Lombardi F, Moschese D, et al
    Evaluation of doravirine-based regimen population target in a large Italian clinical center.
    Antivir Ther. 2021;26.
    PubMed     Abstract available

  32. CICCULLO A, Baldin G, Borghetti A, Di Giambenedetto S, et al
    Real-life findings on the impact of the COVID-19 pandemic on HIV care.
    Antivir Ther. 2021;26.

    January 2021
  33. KOUAME GM, Gabillard D, Moh R, Badje A, et al
    Higher risk of mortality in HIV-HBV co-infected patients from sub-Saharan Africa is observed at lower CD4(+) cell counts.
    Antivir Ther. 2021;26.
    PubMed     Abstract available

  34. LEE JE, Lee SO, Heo J, Kim DW, et al
    Comparative outcomes of lopinavir/ritonavir and hydroxychloroquine for the treatment of COVID-19 with mild-to-moderate severity: A retrospective observational study.
    Antivir Ther. 2021;26.
    PubMed     Abstract available

  35. UGARTE A, De la Mora L, Martinez-Rebollar M, Mallolas J, et al
    An unexpected adverse effect: Elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide-induced cholestasis.
    Antivir Ther. 2021;26.

    June 2020
  36. ZHANG Q, Li X, Qiao S, Shen Z, et al
    Factors influencing hair lamivudine concentration among people living with HIV in Guangxi, China.
    Antivir Ther. 2020 Jun 1. doi: 10.3851/IMP3360.
    PubMed     Abstract available

    April 2020
  37. BLACKMAN AL, Heil EL, Devanathan AS, Pandit NS, et al
    The effect of veno-arterial extracorporeal oxygenation and nasogastric tube administration on the pharmacokinetic profile of abacavir, lamivudine and dolutegravir: a case report.
    Antivir Ther. 2020 Apr 28. doi: 10.3851/IMP3355.
    PubMed     Abstract available

  38. HOFFMANN C, Schewe K, Fenske S, Buhk T, et al
    Short-term neuropsychiatric tolerability of bictegravir combined with emtricitabine/tenofovir alafenamide in clinical practice.
    Antivir Ther. 2020 Apr 1. doi: 10.3851/IMP3351.
    PubMed     Abstract available

    March 2020
  39. ARENAS-PINTO A, Stohr W, Khoo S, Clarke A, et al
    Genital secretion HIV RNA shedding in HIV-positive patients on ritonavir-boosted protease inhibitor monotherapy or standard combination ART: a cross-sectional sub-study from the PIVOT Trial.
    Antivir Ther. 2020 Mar 23. doi: 10.3851/IMP3340.
    PubMed     Abstract available

    February 2020
  40. BARANEK B, Wang S, Cheung AM, Mishra S, et al
    The effect of tenofovir disoproxil fumarate on bone mineral density: a systematic review and meta-analysis.
    Antivir Ther. 2020 Feb 20. doi: 10.3851/IMP3346.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO HIV Infection is free of charge.